Cimetidine Oral Solution and Lynparza (Olaparib Tablets)
Determining the interaction of Cimetidine Oral Solution and Lynparza (Olaparib Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Cimetidine may increase the blood levels of olaparib. In some cases, this can increase the risk and/or severity of side effects such as nausea, vomiting, diarrhea, indigestion, loss of appetite, abdominal pain or discomfort, lung problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. In a drug interaction study with 57 patients, olaparib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.4- and 2.7-fold, respectively, during coadministration with the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase olaparib Cmax by 1.1-fold and AUC by 2-fold. No data are available for use with other, less potent inhibitors. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.
MANAGEMENT: Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected.
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Generic Name: cimetidine
Brand name: Tagamet HB, Tagamet
Synonyms: Cimetidine
Generic Name: olaparib
Brand name: Lynparza
Synonyms: Lynparza
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cimetidine Oral Solution-Lyrica
- Cimetidine Oral Solution-Lyrica (Pregabalin Capsules)
- Cimetidine Oral Solution-Lyrica (Pregabalin Oral Solution)
- Cimetidine Oral Solution-Lyrica CR
- Cimetidine Oral Solution-Lysodren
- Cimetidine Oral Solution-Lysteda
- Lynparza (Olaparib Tablets)-Cimetidine Sodium Chloride
- Lynparza (Olaparib Tablets)-Cimetidine Tablets
- Lynparza (Olaparib Tablets)-Cimzia
- Lynparza (Olaparib Tablets)-Cimzia (Certolizumab Prefilled Syringes)
- Lynparza (Olaparib Tablets)-Cimzia (Certolizumab Vials)
- Lynparza (Olaparib Tablets)-Cinacalcet